News

Cline is recognized for her discoveries about the role of sensory experience in brain development.

Scripps Research chemists devise a new, C-H activation-based method for the synthesis of BCBs.

Liu’s research focuses on the biosynthesis of complex natural products in engineered microbes to harness, alter, or augment their innate bioactivities in the context of drug discovery.

Kelly’s groundbreaking work on protein misfolding has led to therapies for neurodegenerative and cardiovascular diseases.

By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps Research scientists can identify potential new drug targets.

Study tested suvorexant (Belsomra®) for its ability to reduce drug-taking and block relapse.

A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and hypersensitivity.

Major grants from the National Institutes of Health and California Institute for Regenerative Medicine will support the development of state-of-the-art genomic tools.

Scripps Research vaccine candidate headed for clinical trials.

Scripps Research chemists developed a new biologic to work against the synthetic opioid carfentanil, which is 100 times more potent than fentanyl.

Origin-of-life chemists from Scripps Research and the Georgia Institute of Technology propose that glyoxylate could have been the original source of sugars on the “prebiotic” Earth.

Grant renewal from the NIH-NIAID will help uncover critical information about the viruses that cause COVID-19, Lassa and Ebola, including how they evolve.  

Symposium marks public launch of Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)  to develop new antiviral therapies in preparation for future pandemics.

The findings by a Scripps Research team point toward a potential new drug target for treating alcohol use disorder.  

Preliminary results from a Scripps Research and eMed digital medicine study show an unexpectedly high proportion of COVID-19 rebound cases in untreated people, as well as those treated with Paxlovid.

Results from a Scripps Research and UNC team pave the way for a vaccine and therapeutic antibodies that could be stockpiled to fight future coronavirus pandemics.

The five-year grant supports research into the neurobiology of alcohol use disorder.

Scientists at Scripps Research found that apremilast (Otezla®) can reduce alcohol intake by more than half in people with severe alcohol use disorder.

Scripps Research scientists highlight the need for continued monitoring of SARS-CoV-2 and potential variants of concern. 

The discovery triggered development of a new potential drug to eliminate tumor formation.

Calibr transitions investigational compound CLB073 to Gates MRI to advance development.

Advance offers a new way of investigating diseases—including Alzheimer’s, Parkinson’s and different cancers—where mitochondria are disrupted.

Kelly receives the prestigious award for his seminal discoveries in protein-folding mechanics, including developing therapies for severe neurodegenerative and cardiovascular diseases.

Investigational, clinical-stage antidepressant MAP4343 shown to reduce alcohol intake in a mouse model of alcoholism.